Evidence map›Paper›PMID 30133922›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2018

Continuing Challenges in Advancing Preclinical Science in Skeletal Cell-Based Therapies and Tissue Regeneration.

Joseph Featherall, Pamela G Robey, David W Rowe

Abstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A Review of Recent Developments in the Molecular Mechanisms of Bone Healing.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Histological Criteria that Distinguish Human and Mouse Bone Formed Within a Mouse Skeletal Repair Defect.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joseph FeatherallCleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
Pamela G RobeySkeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda MD, USA.
David W RoweCenter for Regenerative Medicine and Skeletal Development, UConn School of Dental Medicine, Farmington, CT, USA.

Funding

The role of stem cells in skeletal health and diseaseZIADE000380 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI ROBEY, PAMELA G · 2009 to 2025
$30.6M
TRANSGENES AS TOOLS TO ASSESS OSTEOBLAST LINEAGER01AR043457 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W. · 1995 to 2009
$2.8M
Targeted Correction of Dominant Mutations of Type I Collagen Causing Severe OIR01AR064381 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W. · 2013 to 2017
$1.7M
Adult Stem Cells: Osteoblast Differentiation and EngraftmentR01AR052374 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W. · 2007 to 2011
$1.5M
Intramural NIH HHS ZIA DE000380NIAMS NIH HHS R01 AR043457NIAMS NIH HHS R01 AR052374NIAMS NIH HHS R01 AR064381
6 · The paper itself

Abstract

Cell-based therapies hold much promise for musculoskeletal medicine; however, this rapidly growing field faces a number of challenges. Few of these therapies have proven clinical benefit, and an insufficient regulatory environment has allowed for widespread clinical implementation without sufficient evidence of efficacy. The technical and biological complexity of cell-based therapies has contributed to difficulties with reproducibility and mechanistic clarity. In order to aid in addressing these challenges, we aim to clarify the key issues in the preclinical cell therapy field, and to provide a conceptual framework for advancing the state of the science. Broadly, these suggestions relate to: (i) delineating cell-therapy types and moving away from "catch-all" terms such as "stem cell" therapies; (ii) clarifying descriptions of cells and their processing; and (iii) increasing the standard of in vivo evaluation of cell-based therapy experiments to determining cell fates. Further, we provide an overview of methods for experimental evaluation, data sharing, and professional society participation that would be instrumental in advancing this field. © 2018 American Society for Bone and Mineral Research.

Indexed as

Biomedical ResearchCell- and Tissue-Based TherapyAnimalsBone and BonesDisease Models, AnimalHumansRegenerationRegenerative MedicineCELL-BASED THERAPIESEXPERIMENTAL REPRODUCIBILITYPRE-CLINICAL MODELSTISSUE ENGINEERING

Identifiers

PMID30133922
PMCPMC6691896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.